The US Patent and Trademark Office (USPTO) has granted a patent titled 'Reticulated elastomeric matrices, their manufacture and use in implantable devices,' for Biomerix Biomaterial platform technology.
The Biomerix Biomaterial is a non-resorbable reticulated, polycarbonate polyurethane-urea, consisting of an open-cell, three-dimensional, interconnected tissue scaffold.
The structure of the biomaterial translates into an ability to support predictable, organised fibrovascular tissue ingrowth and remodeling.
The Biomerix Biomaterial is designed to play a role similar to the body’s extracellular matrix (ECM), through the main phases of inflammation, proliferation and remodeling.
Biomerix said that the material’s structure and chemistry impart differentiated benefits including high porosity, enhanced resilience, long-term durability and superior chemical compatibility over current polymeric materials.
Biomerix president and CEO Kenneth Hayes said that the scope of this technology is far reaching and has the potential to drive technological innovation across a broad spectrum of applications in the medical, industrial, and consumer industries.